Can a targeted drug combo save kidneys in myeloma patients?
NCT ID NCT07085728
First seen May 17, 2026 · Last updated May 17, 2026
Summary
This study tests whether adding daratumumab to standard treatment (bortezomib and dexamethasone) can better improve kidney function in people newly diagnosed with multiple myeloma who also have kidney failure. About 74 adults will receive either the daratumumab combo or the usual combo (cyclophosphamide, bortezomib, dexamethasone) for 4 months. Participants will be followed for up to 10 years to monitor side effects and disease status.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508, United States
Conditions
Explore the condition pages connected to this study.